Together, these data provide compelling in vivo evidence that the prodrug H62 robustly overcomes melanoma resistance to DHODH inhibitors by concurrently targeting mitochondrial pyrimidine metabolism and activating the STING signaling axis, achieving potent antitumor efficacy with no apparent adverse effects. This evidence concerns the gene STING1 and melanoma.